Vir Biotechnology Inc VIR Stock Price Today, Quote, Latest Discussions, Interactive Chart and News

vir stock price

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style. – Data from two ongoing clinical trials in people living with chronic hepatitis B infection suggest the combination of an antiviral with an immunomodulator can achieve rapid and deep declines in hepat…

Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. For the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. The company was incorporated in 2016 and is headquartered in San Francisco, California.

The Phase 2 trial dubbed Peninsula was evaluating VIR-2482 for the … Data are provided ‘as is’ for informational purposes only and are not intended for trading purposes. Data may be intentionally delayed pursuant to supplier requirements.

The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price. Vir Biotechnology, Inc. engages in the provision of technologies to treat and prevent infectious diseases. Its technology platforms include antibody, T cell, innate immunity, and siRNA. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in 2016 and is headquartered in San Francisco, CA. In the first quarter, Vir reported it had $63 million in revenue, down 96.2% year over year.

More value-oriented stocks tend to represent financial services, utilities, and energy stocks. Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The firm’s technology platforms include antibody, T cell, innate immunity and siRNA, which are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in April 7, 2016 and is headquartered in San Francisco, CA. 8 analysts have issued twelve-month price objectives for Vir Biotechnology’s shares. On average, they predict the company’s share price to reach $37.11 in the next year.

Get stock recommendations, portfolio guidance, and more from The Motley Fool’s premium services. Upgrade to MarketBeat All Access to add more stocks to your watchlist. One share of VIR stock can currently be purchased for approximately $10.07. Click the link below and we’ll send you MarketBeat’s list of seven stocks and why their long-term outlooks are very promising. The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Quotes & News

This site is protected by reCAPTCHA and the Google
Privacy Policy and
Terms of Service apply. We’d like to share more about how we work and what drives our day-to-day business. VIR’s beta can be found in Trading Information at the top of this page. A stock’s beta measures how closely tied its price movements have been to the performance of the overall market.

Is it Time to Dump Virios Therapeutics Inc (VIRI) Stock After it Is Up 39.53% in a Week? – InvestorsObserver

Is it Time to Dump Virios Therapeutics Inc (VIRI) Stock After it Is Up 39.53% in a Week?.

Posted: Fri, 18 Aug 2023 07:00:00 GMT [source]

Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue. At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.32% per year. These returns cover a period from January 1, 1988 through July 31, 2023.

Shares of Vir plunged 45% on July 20 after the company reported disappointing study data for its drug candidate to treat influenza A. Choi covers the Healthcare sector, focusing on stocks such as BridgeBio Pharma, PTC Therapeutics, and Ascendis Pharma. According to TipRanks, Choi has an average return of 10.4% and a 52.67% success rate on recommended stocks. The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.

Private Companies

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data. The National Institutes of Health on Wednesday updated its for patients with mild to moderate forms of COVID-19 who are at high risk for disease progression. The new guidelines now include the recently authorized antivira… TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions.

vir stock price

It also said it lost $1.06 in earnings per share (EPS), compared to positive EPS of $3.93 in the same period last year. In Thursday’s announcement, the company said it had $1.9 billion in cash, enough at its current burn rate to probably last into 2027. In a release before the markets opened on Thursday, Vir said that VIR-2482 failed to meet primary or secondary efficacy endpoints as a therapy to treat influenza A illness in a phase 2 trial.

GlaxoSmithKline Beats Expectations Boosted by Covid-19 Treatment. The Stock Is Up.

Vir Biotechnology Inc is a commercial-stage immunology company focused on treating and preventing infectious diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company’s pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB.

Ltd Zurich (23.88%), SB Investment Advisers UK Ltd. (12.43%), BlackRock Inc. (10.41%), State Street Corp (4.04%), Temasek Holdings Private Ltd (3.82%) and Baillie Gifford & Co. (2.97%). The technique has proven to be very useful for finding positive surprises. You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. VIR, +0.92% said Thursday a mid-stage trial of a treatment for symptomatic flu failed to meet its main goals.

Information is provided ‘as-is’ and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart’s disclaimer. Volatility profiles based on trailing-three-year calculations of the standard deviation of service investment returns.

  • The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in 2016 and is headquartered in San Francisco, CA.
  • Style is an investment factor that has a meaningful impact on investment risk and returns.
  • Vir Biotechnology’s shares plunged 45% to a more than three-year low on Thursday after the company’s experimental antibody therapy to prevent a type of flu failed to meet its goals in a mid-stage tria…
  • Dow Jones Industrial Average, S&P 500, Nasdaq, and Morningstar Index (Market Barometer) quotes are real-time.

Shares of Vir Biotechnology Inc. were up 12.8% in premarket trading on Wednesday, the day after it was announced that the stock will join the S&P SmallCap 600 , effective April 4. Vir focuses on immunology therapies to treat infectious diseases. Its only marketed product, Sotrovimab, is an early treatment for COVID-19 that it collaborated with GSK on, but sales of that therapy have been declining. © 2023 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions.

This suggests a possible upside of 268.5% from the stock’s current price. View analysts price targets for VIR or view top-rated stocks among Wall Street analysts. 8 Wall Street research analysts have issued “buy,” “hold,” and “sell” ratings for Vir Biotechnology in the last twelve months. There are currently 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should “moderate buy” VIR shares. Dividend yield allows investors, particularly those interested in dividend-paying stocks,
to compare the relationship between a stock’s price and how it rewards stockholders through dividends.

Company Profile VIR

Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. which of these companies was first named cadabra inc A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return.

American Markets Head for Losing Week – InvestorsObserver

American Markets Head for Losing Week.

Posted: Fri, 08 Sep 2023 13:34:00 GMT [source]

An industry with a larger percentage of Zacks Rank #1’s and #2’s will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4’s and #5’s. Plus, VIR info will be updated daily in your Portfolio Tracker – also free. Compare
VIR’s historical performance
against its industry peers and the overall market. Our Quantitative Research team models direct competitors or comparable companies
from a bottom-up perspective to find companies describing their business in a
similar fashion.

Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. High-growth stocks tend to represent the technology, healthcare, and communications sectors. They rarely distribute dividends to shareholders, opting for reinvestment in their businesses.

AlloVir Inc Ordinary Shares

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style. The scores are based on the trading styles of Value, Growth, and Momentum. There’s also a VGM Score (‘V’ for Value, ‘G’ for Growth and ‘M’ for Momentum), which combines the weighted average of the individual style scores into one score.

Vir Biotechnology’s stock was trading at $25.31 on January 1st, 2023. Since then, VIR shares have decreased by 60.2% and is now trading at $10.07. The collapse of Silicon Valley Bank will leave early-stage biotechnology companies with a funding void, investors and analysts said on Monday, but larger, publicly-traded drug companies should escape … According to 10 analysts, the average rating for VIR stock is “Buy.” The 12-month stock price forecast is $34.0, which is an increase of 238.48% from the latest price.

See which 3 stocks are most likely to make moves following their insider activities. The company has a one-year high of $31.55 and a one-year low of $10.45. Vir Biotechnology has an analyst consensus of Moderate Buy, with a price target consensus of $38.33. 7 employees have rated Vir Biotechnology Chief Executive Officer George Scangos on George Scangos has an approval rating of 85% among the company’s employees.


Sign-up to receive the latest news and ratings for Vir Biotechnology and its competitors with MarketBeat’s FREE daily newsletter. MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation. Zacks Earnings ESP (Expected Surprise Prediction) looks to find companies that have recently seen positive earnings estimate revision activity. The idea is that more recent information is, generally speaking, more accurate and can be a better predictor of the future, which can give investors an advantage in earnings season. The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank. Dow Jones Industrial Average, S&P 500, Nasdaq, and Morningstar Index (Market Barometer) quotes are real-time.

vir stock price

In a report released today, Paul Choi from Goldman Sachs maintained a Buy rating on Vir Biotechnology (VIR – Research Report). Vir Biotechnology’s shares plunged 45% to a more than three-year low on Thursday after the company’s experimental antibody therapy to prevent a type of flu failed to meet its goals in a mid-stage tria… Style is an investment factor that has a meaningful impact on investment risk and returns. Style is calculated by combining value and growth scores, which are first individually calculated. Vir Biotechnology’s stock is owned by a number of retail and institutional investors. Top institutional shareholders include Bank Julius Baer & Co.

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top